Vorinostat was the first HDAC inhibitor entering clinical trials in GBM, which was a phase I trial in 2005 using vorinostat together with Temozolomide (TMZ) to treat patients with malignant gliomas (NCT00268385). Here, HDAC9 is linked to glioblastoma.